Publication: Medium-term clinical outcomes following Xen45 device implantation
Loading...
Official URL
Full text at PDC
Publication Date
2019-11
Authors
Fernández García, Aitor
Zhou, Ying
García Alonso, Mercedes
Andrango, Henry D.
Poyales Galán, Francisco
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Springer Verlag
Citations
Exportar
Abstract
Purpose: To evaluate medium-term clinical outcomes with microstent XEN® 45 Gel Stent (Allergan Dublin, Ireland) for treatment of primary open-angle glaucoma (POAG).
Material and methods: This is a retrospective, descriptive and observational study involving 93 eyes from 63 patients who had undergone POAG surgery with a XEN® 45 Gel Stent implantation and had been followed up and controlled between 12 and 36 months.
Results: IOP dropped from 18.23 ± 5.00 mmHg pre-op to 14.16 ± 2.14, 14.47 ± 2.16 and 14.63 ± 1.91 at 1, 2 and 3 years after surgery (p = 0.000, 0.000 and 0.001) consecutively. Mean number of medications dropped from 1.87 ± 0.94 preoperatively to 0.31 ± 0.69, 0.34 ± 0.63 and 1.00 ± 0.88 (p = 0.000, 0.000 and 0.017) at 12, 24 and 36 months. Mean visual field deviation values never turned out to be significant for any of the follow-up visit data. A total of 94.6% of the surgical procedures turned out to be complication-free. In one surgery, the procedure failed and 18 months later other device was implanted.
Conclusion: POAG surgical procedures with XEN® 45 Gel Stent implants are a safe and effective treatment approach.
Description
Received: 7 august 2019; Accepted: 16 november 2019